Japan Regenerative Medicine

Name

Japan Regenerative Medicine

Legal name

株式会社日本再生医療 (Japan Regenerative Medicine Co., Ltd.)

Website

https://j-rm.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Short description

Japan Regenerative Medicine is a Japanese clinical-stage biotech that developed JRM-001, an autologous Cardiac Stem Cell therapy for pediatric congenital heart disease, based on technology exclusively licensed from Kyoto University; the company was acquired by Metcela and merged in June 2022.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Regenerative medicine
• Cardiac stem cells
• Autologous cell therapy
• Pediatric cardiology
• Cell-based therapeutics

Headquarters

HQ city

Kanagawa

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Regenerative Medicine Product Sales: Once regulatory approval is obtained, the company plans to commercialize its CSC-based regenerative medicine products for pediatric congenital heart disease and other cardiac conditions. Revenue will be generated through product sales to hospitals and healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Japan Regenerative Medicine develops autologous cardiac stem cell (CSC) regenerative medicine products, with its lead candidate JRM-001 targeting pediatric congenital heart disease. The core technology is based on multipotent cardiac-derived stem cells originally developed at Kyoto University and exclusively licensed to JRM, with manufacturing and clinical application guidance from Okayama University. The product is positioned as the world's first CSC-based regenerative medicine for pediatric heart disease and has received Japan's Sakigake (Pioneer) Review Designation.

Differentiator

Problem solved

Functional benefit

Brands

• CSC (Cardiac Stem Cell): Cardiac Stem Cell technology platform developed from Kyoto University research for treating heart diseases

Products and services

• JRM-001 (自家心臓内幹細胞 / Autologous Cardiac Stem Cells) Regenerative medicine product candidate using autologous cardiac stem cells (CSC) for the treatment of pediatric congenital heart diseases in patients where conventional pharmaceuticals, medical devices, and heart transplantation are not viable. Classified as a human cell-processed product; intended for administration at hospitals and pediatric cardiac care centers.
• CSC Platform (心臓内幹細胞 / Cardiac Stem Cell) Cardiac Stem Cell (CSC) technology platform comprising multipotent somatic stem cells found within the heart. The platform underpins JRM's product pipeline targeting severe cardiac disease and is licensed exclusively from Kyoto University with manufacturing and clinical application guidance from Okayama University.

Quantifiable outcome

• Phase 3 clinical trial ongoing for JRM-001 in pediatric congenital heart disease

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• MetSera (株式会社メトセラ)coreStrategic or Co-development Partner · 1 April 2022Acquisition by MetSera in April 2022, making MetSera the parent company. MetSera acquired JRM as a wholly-owned subsidiary, with MetSera continuing as the surviving company in an absorption-type merger in June 2022. This represents a significant consolidation within the Japanese regenerative medicine sector.
• Gene Techno Science (ジーンテクノサイエンス)minorStrategic or Co-development Partner · 1 October 2016Capital and business partnership established in October 2016. This partnership provides strategic support for JRM's business development and potential synergies in the biotechnology sector.
• Okayama UniversitycoreStrategic or Co-development Partner · 1 June 2014Technical transfer agreement for CSC manufacturing methods and clinical applications. Technical guidance received from Professor Wang Yingzheng's research group at Okayama University Hospital's Regenerative Medicine Division. The collaboration includes technology transfer and ongoing research support.
• Kyoto UniversitycoreTechnology or Integration · 1 December 2013Exclusive license agreement for CSC (Cardiac Stem Cell) basic technology patents. This is the foundational partnership that enables JRM's core business of developing CSC-based regenerative medicine products. The license was signed in December 2013.

Scale indicators2 records

Broad incumbents

• Terumo Corporation: Large Japanese medical device and cell therapy company with regenerative medicine operations, including partnerships in cell processing and autologous cell therapy infrastructure. Comparable as a Japanese healthcare major with significant presence in the regenerative medicine ecosystem.
• Healios K.K. Established Japanese regenerative medicine company developing stem cell therapies (MultiStem) for multiple indications including acute respiratory distress and stroke. Comparable as a Japanese-listed regenerative medicine developer operating in the same regulatory environment.

Emerging players

• Cuorips Inc. Japanese pre-clinical biotech developing iPSC-derived cardiac cell therapy for severe heart failure. Comparable as a Japanese cardiac regenerative medicine company with iPSC-derived approach targeting the same therapeutic area.
• Tenaya Therapeutics: US clinical-stage biotech developing gene therapies and cell therapies for heart disease, including TN-201 for genetic cardiomyopathies. Comparable as an emerging cardiac regenerative medicine developer with similar therapeutic area focus.

Direct peers

• Capricor Therapeutics: US clinical-stage biotech developing CAP-1002, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy and other cardiac indications. Directly comparable as a cardiac cell therapy developer with similar cell-based regenerative approach.
• Mesoblast Limited: Australian commercial-stage cell therapy company with Rexlemestrocel-L (revascor) for chronic heart failure and other cardiac indications. Comparable as a late-stage cardiac stem cell therapy developer pursuing similar regenerative mechanism.
• Heartseed Inc. Tokyo-based clinical-stage biotech developing iPSC-derived cardiomyocyte (HS-001) therapy for heart failure. Comparable as a Japanese cardiac regenerative medicine company with late-stage clinical assets and similar regulatory pathway via PMDA.
• Metcela Inc. Parent company of Japan Regenerative Medicine since April 2022 following acquisition and subsequent absorption merger. Metcela is a Japanese clinical-stage biotech focused on cardiac regenerative medicine using VCAM-1-positive cardiac fibroblasts, directly comparable in therapeutic area (cardiac regeneration) and stage (clinical development in Japan).
• BioCardia, Inc. US clinical-stage company developing autologous and allogeneic cell therapies for cardiac disease, including the CardiAMP cell therapy system for heart failure. Comparable in cardiac cell therapy development approach and target indications.

Others

• Cytokinetics, Incorporated: US late-stage biopharmaceutical company developing cardiac myosin modulators (e.g., omecamtiv mecarbil, aficamten) for heart failure. Adjacent comparable in the cardiac therapeutics space, though pursuing small-molecule rather than cell-based regenerative approaches.

Market position

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Japan Regenerative Medicine